Interleukin-33 in health and disease

  • Nat Rev Immunol. 2016 Nov;16(11):676-689. doi: 10.1038/nri.2016.95.
Foo Yew Liew  1  2 ,  Jean-Philippe Girard  3 ,  Heth Roderick Turnquist  4
Affiliations
  • 1. Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G3 8HF, UK.
  • 2. School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215006, China.
  • 3. Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, 31077 Toulouse, France.
  • 4. Starzl Transplantation Institute, and the Departments of Surgery and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
PMID: 27640624 DOI: 10.1038/nri.2016.95
Abstract

Interleukin-33 (IL-33) - a member of the IL-1 family - was originally described as an inducer of type 2 immune responses, activating T helper 2 (TH2) cells and mast cells. Now, evidence is accumulating that IL-33 also potently stimulates group 2 innate lymphoid cells (ILC2s), regulatory T (Treg) cells, TH1 cells, CD8+ T cells and natural killer (NK) cells. This pleiotropic nature is reflected in the role of IL-33 in tissue and metabolic homeostasis, Infection, inflammation, Cancer and diseases of the central nervous system. In this Review, we highlight the molecular and cellular characteristics of IL-33, together with its major role in health and disease and the potential therapeutic implications of these findings in humans.

Products